US House Appropriators Have Little Left To Say About Allowing Cannabinoids In Supplements

Appropriation Committee’s report with FDA’s FY2022 funding bill appears to signal that other than getting something done, members have little to say about establishing lawful use of hemp-derived cannabinoids in non-drug products.